Pharmaceutical EVP & Counsel awarded stock units

Pharmaceutical, Inc. executive vice president and general counsel David Dieter reported several equity compensation transactions.

Rhea-AI Filing Summary

Pharmaceutical, Inc. executive vice president and general counsel David Dieter reported several equity compensation transactions. He acquired 22,194 restricted stock units at $0 and 9,005 performance share units after performance goals were confirmed, also at $0. To cover tax withholding on vested performance units, 2,781 shares were disposed of at $46.75. After these transactions, he directly owned 97,271 shares of common stock. The new RSUs vest one-third on February 10, 2027, with the remainder vesting in equal annual installments over the following two years, contingent on his continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Dieter David

Role EVP & General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	22,194	$0.00	$0.00
Grant/Award	Common Stock	9,005	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	2,781	$46.75	$130K

Holdings After Transaction: Common Stock — 97,271 shares (Direct)

Footnotes (4)

1. F1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
2. F2. Includes 404 shares acquired on January 16, 2026 under the Issuer's employee stock purchase plan.
3. F3. Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 9,005 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year.
4. F4. Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did COLL executive David Dieter report on this Form 4?

David Dieter reported equity compensation activity, including stock unit grants and tax withholding. He received 22,194 restricted stock units and 9,005 performance share units, and 2,781 shares were withheld and disposed of at $46.75 to satisfy tax obligations on vested performance units.

How many restricted stock units did COLL EVP David Dieter receive?

He received a grant of 22,194 restricted stock units at $0 per unit. Each unit represents a contingent right to one common share, vesting one-third on February 10, 2027, with the remaining two-thirds vesting in equal annual installments over the following two years.

What performance share units vested for COLL executive David Dieter?

An aggregate of 9,005 performance share units vested after the compensation committee determined performance criteria were met. These units were granted in the issuer’s 2025 fiscal year and converted into common stock, contributing to Dieter’s increased direct ownership reported in this Form 4 filing.

Why were 2,781 COLL shares disposed of by David Dieter?

The 2,781 shares were withheld and disposed of by the issuer at $46.75 per share to cover applicable withholding taxes. This tax-related disposition occurred upon the vesting of performance share units, a common mechanism to satisfy tax liabilities on equity compensation.

How many COLL common shares does David Dieter own after these transactions?

Following the reported equity awards and tax withholding, David Dieter directly owned 97,271 shares of common stock. This figure reflects his updated beneficial ownership after receiving restricted and performance share units and having a portion of shares withheld for tax obligations.

What is the vesting schedule for David Dieter’s new RSUs at COLL?

The 22,194 restricted stock units vest over three years. One-third vests on February 10, 2027, and the remaining two-thirds vest in equal annual installments over the next two years, subject to his continued service, with settlement in common stock at each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dieter David

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MA 02072

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		22,194(1)	A	$0	91,047(2)	D
Common Stock	02/10/2026		A		9,005(3)	A	$0	100,052	D
Common Stock	02/10/2026		F		2,781(4)	D	$46.75	97,271	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

2. Includes 404 shares acquired on January 16, 2026 under the Issuer's employee stock purchase plan.

3. Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 9,005 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year.

4. Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.

	/s/ Colleen Tupper as Attorney-In-Fact For David Dieter	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.